John Jayachandran, MD
Clinical Cardiac Electrophysiology · Fort Worth, TXNPI 1730164526
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,765 of the $3,122 with a category attached, or 88.6%. 20 manufacturers reported payments, led by Abbott at 25.7% of the total. Reporting peaked in 2024 at $1,449 and has fallen 87.6% since, to $179 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in TX, where the typical reported total is $27,892.
Across 122 payments — averaging $25.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$804
- Biosense Webster, Inc.$461
- Pfizer$359
- Novartis$181
- Sanofi-aventis U.S. LLC$178
- Boehringer Ingelheim$175
- plus $964 from 14 others
Across 175 payments — averaging $403.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$51K
- Biotronik Inc.$9K
- Abbott$4K
- Boston Scientific$4K
- Merck$3K
What the payments were for
- Travel & lodging$35711%
- Food & beverage$2,76589%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 16 | $804 |
| Biosense Webster, Inc. | 16 | $461 |
| Pfizer | 24 | $359 |
| Novartis | 9 | $181 |
| Sanofi-aventis U.S. LLC | 10 | $178 |
| Boehringer Ingelheim | 7 | $175 |
| Heartflow, Inc. | 1 | $134 |
| Biotronik Inc. | 1 | $124 |
| E.r. Squibb & Sons, L.L.C. | 7 | $120 |
| Johnson & Johnson(2 entities) | 7 | $107 |
| AstraZeneca | 5 | $86 |
| Inspire Medical Systems, Inc. | 3 | $81 |
| Boston Scientific | 3 | $78 |
| Merck | 3 | $68 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $50 |
| Amgen | 2 | $37 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $36 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
| Altathera Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$461
- FFRct$134
- Orsiro Mission$124
How this compares
$3,122 in reported general payments places this provider in the 5th percentile of 233 clinical cardiac electrophysiology providers in Texas.
See all clinical cardiac electrophysiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 218 | $199,094 |
| MultaqDronedarone Hcl | 46 | $60,133 |
| EntrestoSacubitril/Valsartan | 23 | $33,316 |
| JardianceEmpagliflozin | 43 | $30,857 |
| XareltoRivaroxaban | 17 | $21,997 |
| Flecainide Acetate | 55 | $2,319 |
| Propafenone Hcl | 67 | $2,078 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 62 | $1,590 |
| SotalolSotalol Hcl | 38 | $984 |
| Amiodarone Hcl | 65 | $789 |
| Digoxin | 33 | $737 |
| Metoprolol Succinate | 69 | $709 |
| Diltiazem 24hr Er (Xr)Diltiazem Hcl | 11 | $469 |
| Carvedilol | 39 | $324 |
| Irbesartan | 12 | $306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $359 | $199,094218 claims |
| Sanofi-aventis U.S. LLCMultaq | $178 | $60,13346 claims |
| NovartisEntresto | $181 | $33,31623 claims |
| Boehringer IngelheimJardiance | $175 | $30,85743 claims |
| Johnson & JohnsonXarelto | $107 | $21,99717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 233 clinical cardiac electrophysiology providers in Texas.
Other clinical cardiac electrophysiology in Fort Worth
- Theodore TakataFort Worth$396K
- Aleem MughalFort Worth$112K
- Senthil ThambidoraiFort Worth$100K
- Michael DelaughterBedford$1.6M
- Andrea NataleAustin$1.3M
- Jason ZagrodzkyAustin$961K
- Amin Al-AhmadAustin$771K
- Dale YooMcKinney$585K
- Rodney HortonAustin$553K
- Jose Cuellar SilvaWebster$502K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.